ScreenerHero

INMB INmune Bio Inc.

NAS · US · Healthcare · Biotechnology · inmunebio.com
1.860USD-0.53%Mkt Cap: 51.62M $P/E: —

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product cand…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap51.62M USD
Enterprise Value34.89M USD
Revenue (TTM)0 USD
Gross Profit0 USD
Net Income (TTM)-45.93M USD
Revenue/Share0.00 USD
Last Price1.860 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.82
PEG—
EV/EBITDA—
EV/Revenue—
P/SInfinity
P/B2.54
EPS (TTM)-0.64
EPS (Forward)-0.49
52W Range
1.09051% of range2.600
52W High2.600 USD
52W Low1.090 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-91866.00%
ROE-195.26%
ROA-141.98%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.58M USD
CapEx (TTM)1.04M USD
FCF Margin—
FCF Yield-19.46%
Net Debt-17.01M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.04
Current Ratio4.04
Quick Ratio3.94
Book Value/Sh0.74 USD
Cash/Share0.66 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.000 USD
Upside (mean)+276.3%
Target Range4.000 USD – 9.000 USD
4.000+276.3% to mean9.000
# Analysts3
Ownership
Shares Out.27.75M
Float23.30M
Insiders10.75%
Institutions15.56%
Short Interest
Short Ratio7.0d
Short % Float9.08%
Short % Out.8.11%
Shares Short2.25M
Short (prev mo.)2.10M
Technical
SMA 502.123 (-12.4%)
SMA 2001.638 (+13.6%)
Beta0.90
S&P 52W Chg16.45%
Avg Vol (30d)333.85K
Avg Vol (10d)280.20K
Technical Indicators
RSI (14)36.0
MACD-0.0735
MACD Signal-0.0352
MACD Hist.-0.0383
BB Upper2.525 USD
BB Middle2.117 USD
BB Lower1.709 USD
BB Width38.59%
ATR (14)0.1241 USD
Vol Ratio (20d)0.30x